A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma

Neuro-Oncology

Volumn 5, Issue 2, 2003, Pages 96-103

  Prados, Michael D ^a   Schold Jr , S Clifford ^b   Fine, Howard A ^c   Jaeckle, Kurt ^d   Hochberg, Fred ^e   Mechtler, Laszlo ^f   Fetell, Michael R ^g   Phuphanich, Surasak ^h   Feun, Lynn ⁱ   Janus, Todd J ^j   Ford, Kathleen ^k   Graney, William ^k  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f UNIVERSITY AT BUFFALO   (United States)

^g New York Presbyterian Hospital Columbia University Medical Center   (United States)

^h H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^k ALKERMES INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; LOBRADIMIL; NITROSOUREA;

ABDOMINAL PAIN; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BACKACHE; BLOOD BRAIN BARRIER; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEBRILE NEUTROPENIA; FEMALE; FUNCTIONAL ASSESSMENT; GLIOBLASTOMA; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROPSYCHOLOGICAL TEST; PERMEABILITY BARRIER; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TACHYCARDIA; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR RECURRENCE; VASCULAR DISEASE; VISUAL DISORDER;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BRADYKININ; CARBOPLATIN; CONFIDENCE INTERVALS; DOUBLE-BLIND METHOD; FEMALE; GLIOBLASTOMA; GLIOMA; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE;

EID: 0037388250     PISSN: 15228517     EISSN: None     Source Type: Journal    
DOI: 10.1215/S1522851702000340     Document Type: Article

References (15)

1. Bartus, R.T., Elliott, P.J., Hayward, N.J., Deen, R.L., McEwen, E., and Fisher, S.K. (1996a) Permeability of the blood brain barrier by the bradykinin agonist, RMP-7: Evidence for a sensitive, auto-regulated, receptor-mediated system. Immunopharmacology 33, 270-278.
2. Bartus, R.T., Elliott, P.J., Dean, R.L., Hayward, N.J., Nagle, R.L., Huff, M.R., Snodgrass, P.A., and Blunt, D.G. (1996b) Controlled modulation of the BBB permeability using the bradykinin agonist, RMP-7. Exp. Neurol. 142, 14-28.
3. Bartus, R.T., Snodgrass, P., Marsh, J., Agostino, M., Perkins, A., and Emerich, D.F. (2000) Intravenous Cereport (RMP-7) modifies topographic uptake profile of carboplatin within rat glioma and brain surrounding tumor, elevates platinum levels, and enhances survival. J. Pharmacol. Exp. Ther. 293, 903-911.
4. Cloughesy, T., Black, K.L., Gobin, Y., Farahani, K., Nelson, G., Villablanca, P., Kabbinavar, F., Vinuela, F., and Wortel, C. (1999) Intra-arterial Cereport (RMP-7) and carboplatin: A dose escalation study for recurrent malignant gliomas. Neurosurgery 44, 270-278.
5. Elliott, P.J., Hayward, N.J., Deen, R.L., Blunt, D.G., and Bartus, R.T. (1996) Intravenous RMP-7 selectively increases uptake of carboplatin into rat brain tumors. Cancer Res. 56, 3998-4005.
6. Emerich, D.F., Snodgrass, P., Dean, R., Agnostino, M., Hasler, B., Pink, M., Xiong, H., Kim, B.S., and Bartus, R.T. (1999) Enhanced delivery of carboplatin into brain tumours with intravenous Cereport (RMP-7): Dramatic differences and insight gained from dosing parameters. Br. J. Cancer 80, 964-970.
7. Gregor, A., Lind, M., Newman, H., Grant, R., Hadley, D.M., Barton, T., and Osborn, C. (1999) Phase II studies of RMP-7 and carboplatin in the treatment of recurrent high grade glioma. J. Neurooncol. 44, 137-145.
8. Kroll, R.A., and Neuwelt, E.A. (1998) Outwitting the blood-brain barrier for therapeutic purposes: Osmotic opening and other means. Neurosurgery 42, 1083-1100.
9. Macdonald, D.R., Cascino, T.L., Schold, S.C., and Cairncross, J.G. (1990) Response criteria for phase II studies of supratentorial malignant glioma. J. Clin. Oncol. 8, 1277-1280.
10. Matsukado, K., Inamura, T., Nakano, S., Fukui, M., Bartus, R.T., and Black, K.L. (1996) Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7. Neurosurgery 39, 125-134.
11. Nomura, T., Inamura, T., and Black, K.L. (1994) Intracarotid infusion of bradykinin selectively increases blood-tumor permeability in 9L and C6 brain tumors. Brain Res. 659, 62-66.
12. Pardridge, W.M. (1997) Drug delivery to the brain. J. Cereb. Blood Flow Metab. 17, 713-731.
13. Raymond, J., Robertson, D., and Dinsdale, H. (1986) Pharmacological modification of bradykinin induced breakdown of the blood-brain barrier. Can. J. Neurol. Sci. 13, 214-220.
14. Warnick, R.E., Prados, M.D., Mack, E.E., Chandler, K.L., Doz, F., Rabbitt, J.E., and Malec, M.K. (1994) A phase II study of intravenous carboplatin for the treatment of recurrent gliomas. J. Neurooncol. 19, 69-74.
15. Yung, W.K.A., Mechtler, L., and Gleason, M.J. (1991) Intravenous carboplatin for recurrent malignant glioma: A phase II study. J. Clin. Oncol. 9, 860-864.